Share on LinkedInShare on LinkedIn

ARTICLE · 29 JANUARY 2024

HHS Drops Appeal In Drug Coupon Case

Groom Law Group, Chartered
Groom Law Group, Chartered
Contributor
Groom Law Group, Chartered

Groom Law Group, Chartered

Groom Law Group has been at the forefront of developments in the nation’s benefits, health, and...

View firm profile
Explore more from Groom Law Group, Chartered

On January 16, 2024, the Department of Health and Human Services ("HHS") dropped its appeal of the U.S. District Court for the District of Columbia's September 29, 2023...

United StatesLitigation, Mediation & Arbitration

On January 16, 2024, the Department of Health and Human Services ("HHS") dropped its appeal of the U.S. District Court for the District of Columbia's September 29, 2023 decision that vacated a portion of the 2021 Notice of Benefit and Payment Parameters ("2021 NBPP"). The 2021 NBPP permitted (but did not require) plans and issuers to count direct support offered by drug manufacturers for prescription drugs ("Coupons") toward the Affordable Care Act's annual cost-sharing limit ("MOOP"). HIV and Hepatitis Policy Inst. et al. v. U.S. Dep't of Health and Hum. Svcs., No. 22-2604, 2023 WL 6388932 (D.D.C. Sept. 29, 2023). See our prior alert here.

Although HHS dropped its appeal, HHS has adopted non-enforcement relief. Thus, until HHS issues further guidance, HHS will not take enforcement action against plans and issuers that do not count Coupons towards the MOOP.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from